Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.
Morabito A, Gebbia V, Di Maio M, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G, Gridelli C, Gallo C, Perrone F. Morabito A, et al. Among authors: giordano p. Lung Cancer. 2013 Jul;81(1):77-83. doi: 10.1016/j.lungcan.2013.04.008. Epub 2013 May 1. Lung Cancer. 2013. PMID: 23643177 Clinical Trial.
Time spent for activation of non-profit studies in oncology in Italy.
De Feo G, Signoriello S, Bryce JC, Del Giudice A, Canzanella G, Crudele F, Romano F, de Matteis G, Florio M, Falasconi F, Savio A, Giordano P, Daniele G, Iaccarino M, Piccirillo MC, Di Maio M, Morabito A, Gallo C, Perrone F. De Feo G, et al. Among authors: giordano p. PLoS One. 2010 Jul 29;5(7):e11864. doi: 10.1371/journal.pone.0011864. PLoS One. 2010. PMID: 20686686 Free PMC article.
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F. Morabito A, et al. Among authors: giordano p. Drugs Today (Barc). 2010 Sep;46(9):683-98. doi: 10.1358/dot.2010.46.9.1516989. Drugs Today (Barc). 2010. PMID: 20967300 Review.
Pharmacokinetic evaluation of zoledronic acid.
De Luca A, Lamura L, Gallo M, Daniele G, D'Alessio A, Giordano P, Maiello MR, Pergameno M, Perrone F, Normanno N. De Luca A, et al. Among authors: giordano p. Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):911-8. doi: 10.1517/17425255.2011.585156. Epub 2011 May 13. Expert Opin Drug Metab Toxicol. 2011. PMID: 21563999 Review.
Gefitinib in non small cell lung cancer.
Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A. Costanzo R, et al. Among authors: giordano p. J Biomed Biotechnol. 2011;2011:815269. doi: 10.1155/2011/815269. Epub 2011 May 23. J Biomed Biotechnol. 2011. PMID: 21660144 Free PMC article. Review.
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials.
Di Maio M, Signoriello S, Morabito A, Rossi A, Maione P, Piantedosi F, Bilancia D, Cigolari S, Barbera S, Gebbia V, Daniele B, Robbiati SF, Illiano A, Ceribelli A, Carrozza F, Favaretto A, Piazza E, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Rocco G, Gallo C, Perrone F, Gridelli C. Di Maio M, et al. Among authors: giordano p. Lung Cancer. 2012 Jun;76(3):457-64. doi: 10.1016/j.lungcan.2012.01.002. Epub 2012 Jan 31. Lung Cancer. 2012. PMID: 22297086
Cetuximab in non-small-cell lung cancer.
Carillio G, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, Daniele G, Giordano P, Bryce J, Normanno N, Rocco G, Perrone F, Morabito A. Carillio G, et al. Among authors: giordano p. Expert Rev Anticancer Ther. 2012 Feb;12(2):163-75. doi: 10.1586/era.11.178. Expert Rev Anticancer Ther. 2012. PMID: 22316364 Review.
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, Landi G, Rossi E, Pacilio C, Labonia V, Di Rella F, Bartiromo A, Buonfanti G, De Feo G, Esposito G, D'Aniello R, Maiolino P, Signoriello S, De Maio E, Tinessa V, Colantuoni G, De Laurentiis M, D'Aiuto M, Di Bonito M, Botti G, Giordano P, Daniele G, Morabito A, Normanno N, de Matteis A, Perrone F. Nuzzo F, et al. Among authors: giordano p. Ann Oncol. 2012 Aug;23(8):2027-2033. doi: 10.1093/annonc/mdr600. Epub 2012 Mar 12. Ann Oncol. 2012. PMID: 22412041 Free article. Clinical Trial.
837 results